New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.
Tri Doan, MD, PhD
Advertisement
Dr Doan is a postdoctoral fellow at Mass General Brigham and Harvard Medical School.
Articles by Tri Doan, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation
2
Future DSM Plans Overlook Core Problem of Validity
3
Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease
4
Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia
5